uniQure Faces Severe Rebuke from FDA Amid Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2026
0mins
Should l Buy QURE?
Source: Globenewswire
- FDA Rebuke: An FDA official publicly labeled uniQure's AMT-130 gene therapy candidate as a 'failed therapy,' accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgical Requirement Controversy: The FDA official dismissed uniQure's ethical concerns regarding 'sham surgeries,' clarifying that the agency did not request 'drilling holes in skulls' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially impacting the design and implementation of the company's clinical trials.
- Legal Action Update: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, which may lead to diminished investor trust in the company's transparency.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, or risk losing the opportunity to represent their interests in the lawsuit, further affecting their investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 17.090
Low
33.00
Averages
49.88
High
70.00
Current: 17.090
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
uniQure Faces Class Action Lawsuit Notification
- Class Action Initiation: Levi & Korsinsky LLP has notified investors that uniQure N.V. is facing a class action lawsuit aimed at recovering losses for investors affected between September 24, 2025, and October 31, 2025, indicating significant legal risks that could impact the company's stock performance.
- Allegations Overview: The lawsuit alleges that uniQure's pivotal study design was not fully approved by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline due to the need for additional studies, which may undermine investor confidence in the company's future prospects.
- Investor Rights Protection: Affected investors have until April 13, 2026, to request to be appointed as lead plaintiff, allowing them to participate in the lawsuit and potentially receive compensation without any out-of-pocket costs, providing a legal recourse for investors.
- Law Firm Credentials: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, highlighting its expertise and credibility in handling such cases.
See More
uniQure Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against uniQure N.V. for violations of securities laws related to trading from September 24 to October 31, 2025, which could negatively impact the company's reputation and stock price.
- False Statement Allegations: The complaint alleges that uniQure made false and misleading statements to the market, failing to secure full FDA approval for its pivotal study, resulting in investor losses when the truth emerged.
- Investor Rights Protection: The Schall Law Firm encourages investors who purchased uniQure securities during the class period to contact them before April 13, 2026, to participate in the lawsuit and seek compensation for losses, demonstrating a commitment to protecting investor rights.
- Legal Process Status: The class action has not yet been certified, meaning investors are not represented by an attorney during this period, highlighting the importance of proactive participation in legal proceedings for investors.
See More
Reminder for uniQure N.V. Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action lawsuit and potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status and delays in its Biologics License Application for its Huntington's disease drug candidate, resulting in investor losses when the truth emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries, which could affect potential compensation outcomes.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Criticism: In March 2026, an FDA official publicly labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgery Requirement Controversy: The FDA official dismissed uniQure's ethical concerns regarding 'sham surgeries,' clarifying that the agency did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially impacting the company's compliance in clinical trials.
- Legal Action Developments: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, leading to a 49% stock drop on November 3, 2025, highlighting serious deficiencies in the company's disclosures.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, or risk losing the opportunity to represent their interests in the lawsuit, which could further affect their investment decisions regarding uniQure.
See More
Faruqi & Faruqi Encourages UniQure Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against UniQure N.V., particularly for investors who purchased securities between September 24, 2025, and October 31, 2025, aiming to safeguard investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options and seek assistance.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against UniQure is April 13, 2026, emphasizing the importance of timely action.
- Investor Rights Protection: This legal action aims to provide a platform for affected investors to pursue potential compensation through a class action lawsuit, reflecting a commitment to protecting investor rights.
See More
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
uniQure Faces Class Action Lawsuit Notification
- Class Action Initiation: Levi & Korsinsky LLP has notified investors that uniQure N.V. is facing a class action lawsuit aimed at recovering losses for investors affected between September 24, 2025, and October 31, 2025, indicating significant legal risks that could impact the company's stock performance.
- Allegations Overview: The lawsuit alleges that uniQure's pivotal study design was not fully approved by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline due to the need for additional studies, which may undermine investor confidence in the company's future prospects.
- Investor Rights Protection: Affected investors have until April 13, 2026, to request to be appointed as lead plaintiff, allowing them to participate in the lawsuit and potentially receive compensation without any out-of-pocket costs, providing a legal recourse for investors.
- Law Firm Credentials: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, highlighting its expertise and credibility in handling such cases.
See More
uniQure Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against uniQure N.V. for violations of securities laws related to trading from September 24 to October 31, 2025, which could negatively impact the company's reputation and stock price.
- False Statement Allegations: The complaint alleges that uniQure made false and misleading statements to the market, failing to secure full FDA approval for its pivotal study, resulting in investor losses when the truth emerged.
- Investor Rights Protection: The Schall Law Firm encourages investors who purchased uniQure securities during the class period to contact them before April 13, 2026, to participate in the lawsuit and seek compensation for losses, demonstrating a commitment to protecting investor rights.
- Legal Process Status: The class action has not yet been certified, meaning investors are not represented by an attorney during this period, highlighting the importance of proactive participation in legal proceedings for investors.
See More
Reminder for uniQure N.V. Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action lawsuit and potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval status and delays in its Biologics License Application for its Huntington's disease drug candidate, resulting in investor losses when the truth emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries, which could affect potential compensation outcomes.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Criticism: In March 2026, an FDA official publicly labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgery Requirement Controversy: The FDA official dismissed uniQure's ethical concerns regarding 'sham surgeries,' clarifying that the agency did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially impacting the company's compliance in clinical trials.
- Legal Action Developments: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, leading to a 49% stock drop on November 3, 2025, highlighting serious deficiencies in the company's disclosures.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, or risk losing the opportunity to represent their interests in the lawsuit, which could further affect their investment decisions regarding uniQure.
See More
Faruqi & Faruqi Encourages UniQure Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against UniQure N.V., particularly for investors who purchased securities between September 24, 2025, and October 31, 2025, aiming to safeguard investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options and seek assistance.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against UniQure is April 13, 2026, emphasizing the importance of timely action.
- Investor Rights Protection: This legal action aims to provide a platform for affected investors to pursue potential compensation through a class action lawsuit, reflecting a commitment to protecting investor rights.
See More
